Ye Wang

Dr. Ye Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Molecules
Verified
Journal Article
Open access
PDF file
YWYe Wang
Ye Wang
HZHonggang Zhao
Honggang Zhao
SSSimone Sciabola
Simone Sciabola
WWWenlu Wang
Wenlu Wang
Deep generative models applied to the generation of novel compounds in small-molecule drug design have attracted a lot of attention in recent years. To design compounds that interact with specific target proteins, we propose a Generative Pre-Trained Transformer (GPT)-inspired model for de novo target-specific molecular design. By implementing different keys and values for the multi-head attention conditional on a specified target, the proposed method can generate drug-like compounds both with and without a specific target. The results show that our approach (cMolGPT) is capable of generating SMILES strings that correspond to both drug-like and active compounds. Moreover, the compounds generated from the conditional model closely match the chemical space of real target-specific molecules and cover a significant portion of novel compounds. Thus, the proposed Conditional Generative Pre-Trained Transformer (cMolGPT) is a valuable tool for de novo molecule design and has the potential to accelerate the molecular optimization cycle time.

2 August 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
ABAlbert Bou
Albert Bou
MTMorgan Thomas
Morgan Thomas
SDSebastian Dittert
Sebastian Dittert
CNCarles Navarro
Carles Navarro
MMMaciej Majewski
Maciej Majewski
GFGianni De Fabritiis
Gianni De Fabritiis
In recent years, reinforcement learning (RL) has emerged as a valuable tool in drug design, offering the potential to propose and optimize molecules with desired properties. However, striking a balance between capabilities, flexibility, reliability, and efficiency remains challenging due to the complexity of advanced RL algorithms and the significant reliance on specialized code. In this work, we introduce ACEGEN, a comprehensive and streamlined toolkit tailored for generative drug design, built using TorchRL, a modern RL library that offers thoroughly tested reusable components. We validate ACEGEN by benchmarking against other published generative modeling algorithms and show comparable or improved performance. We also show examples of ACEGEN applied in multiple drug discovery case studies. ACEGEN is accessible at https://github.com/acellera/acegen-open and available for use under the MIT license.

5 March 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
ZCZhonglin Cao
Zhonglin Cao
SSSimone Sciabola
Simone Sciabola
YWYe Wang
Ye Wang

13 January 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
WHWenxing Hu
Wenxing Hu
KLKejie Li
Kejie Li
JGJake Gagnon
Jake Gagnon
YWYe Wang
Ye Wang
TRTalia Raney
Talia Raney
Baohong ZhangBaohong Zhang
Baohong Zhang
Early-stage detection of neurodegenerative diseases is crucial for effective clinical treatment. However, current diagnostic methods are expensive and time-consuming. In this study, we present FundusNet, a deep-learning model trained on fundus images, for rapid and cost-effective diagnosis of neurodegenerative diseases. FundusNet achieved superior performance in age prediction (MAE 2.55 year), gender classification (AUC 0.98), and neurodegenerative disease diagnosis—Parkinson’s disease AUC 0.75 ± 0.03, multiple sclerosis AUC 0.77 ± 0.02. Grad-CAM was used to identify which part of the image contributes to diagnosis. Imaging biomarker interpretation demonstrated that FundusNet effectively identifies clinical retina structures associated with diseases. Additionally, the model’s high accuracy in predicting genetic risk suggests that its performance could be further enhanced with larger training datasets.

30 October 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
RARasha Atwi
Rasha Atwi
YWYe Wang
Ye Wang
SSSimone Sciabola
Simone Sciabola
AAAdam Antoszewski
Adam Antoszewski

13 February 2024 in Molecules
Verified
Journal Article
Open access
PDF file
NBNupur Bansal
Nupur Bansal
YWYe Wang
Ye Wang
SSSimone Sciabola
Simone Sciabola
The rank ordering of ligands remains one of the most attractive challenges in drug discovery. While physics-based in silico binding affinity methods dominate the field, they still have problems, which largely revolve around forcefield accuracy and sampling. Recent advances in machine learning have gained traction for protein–ligand binding affinity predictions in early drug discovery programs. In this article, we perform retrospective binding free energy evaluations for 172 compounds from our internal collection spread over four different protein targets and five congeneric ligand series. We compared multiple state-of-the-art free energy methods ranging from physics-based methods with different levels of complexity and conformational sampling to state-of-the-art machine-learning-based methods that were available to us. Overall, we found that physics-based methods behaved particularly well when the ligand perturbations were made in the solvation region, and they did not perform as well when accounting for large conformational changes in protein active sites. On the other end, machine-learning-based methods offer a good cost-effective alternative for binding free energy calculations, but the accuracy of their predictions is highly dependent on the experimental data available for training the model.